Trial Launched to Treat Parkinson’s with Reprogrammed Stem Cells

Trial Launched to Treat Parkinson’s with Reprogrammed Stem Cells

Surgeons will inject approximately 5 million dopamine-producing progenitor cells into patients’ brains.

Diana Kwon
Diana Kwon

Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other...

View full profile.

Learn about our editorial policies.

Jul 31, 2018

On Monday (July 30), researchers at Kyoto University in Japan announced that they were launching a clinical trial to treat Parkinson’s disease using reprogrammed adult stem cells. 

“This will be the world’s first clinical trial using [induced pluripotent stem] cells on Parkinson’s disease,” Jun Takahashi, a neurosurgeon at Kyoto University’s Centre for iPS Cell Research and Application, told reporters (via Reuters). 

Takahashi and his colleagues will inject dopamine-producing neural progenitor cells—derived from induced pluripotent stem cells (iPSCs) from healthy adult donors—into Parkinson’s patients’ brains. Approximately 5 million cells will be injected into the patients’ striatum (in red above), the primary brain region implicated in the disease. 

The team plans to recruit seven participants and to observe each patient for two years after the injection. 

Last year, Takahashi and his colleagues reported that the injected cells could survive in monkey brains for up to two years, and that the...

See “Parkinson’s Disease Cell Therapy Relieves Symptoms in Monkeys

According to Science, this is the third iPSC clinical trial approved in Japan. The other two are aimed at treating age-related macular degeneration and heart disease.